Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome?
Saved in:
Main Authors: | Simone U. Dalm (Author), Marion de Jong (Author) |
---|---|
Format: | Book |
Published: |
SpringerOpen,
2017-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors
by: Sofia Koustoulidou, et al.
Published: (2022) -
Head-to-Head Comparison of SSTR Antagonist [<sup>68</sup>Ga]Ga-DATA<sup>5m</sup>-LM4 with SSTR Agonist [<sup>68</sup>Ga]Ga-DOTANOC PET/CT in Patients with Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Imaging Study
by: Rahul Viswanathan, et al.
Published: (2024) -
Tetramethylpyrazine Improves Cognitive Function of Alzheimer’s Disease Mice by Regulating SSTR4 Ubiquitination
by: Weng G, et al.
Published: (2021) -
eTFC-01: a dual-labeled chelate-bridged tracer for SSTR2-positive tumors
by: Dylan Chapeau, et al.
Published: (2024) -
Favorable SSTR subtype selectivity of SiTATE: new momentum for clinical [18F]SiTATE PET
by: Carmen Wängler, et al.
Published: (2022)